Skip to main content

Table 4 Analysis of number of puffs of study medication and open-label albuterol used during day and separately at night (mean changes from study baselinea) at the end of the 4-week treatment period

From: Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial

 

ALB-HFA

CVT-MDI

Difference (CVT-MDI – ALB-HFA)

Endpoint

n

Mean

SE

N

Mean

SE

Mean

95 % CI

p value

Weekly meanb number of AM puffs of study medication used

176

−0.49

0.07

178

−0.53

0.07

−0.04

(−0.17, 0.08)

0.510

Weekly meanb number of PM puffs of study medication used

178

−0.10

0.05

180

−0.12

0.05

−0.02

(−0.12, 0.08)

0.659

Weekly meanb number of AM puffs of open label ALB-HFA used

176

−2.24

0.05

178

−2.28

0.05

−0.04

(−0.14, 0.05)

0.363

Weekly meanb number of PM puffs of open label ALB-HFA used

178

−0.92

0.02

180

−0.93

0.02

−0.01

(−0.06, 0.04)

0.679

  1. SE standard error, 95 % CI 95 % confidence interval, ALB-HFA albuterol hydrofluoroalkaline, CVT-MDI ipratropium bromide/albuterol sulfate metered-dose inhaler
  2. aMean observed in last week prior to administration of the first dose of the randomized treatment
  3. bWeekly mean number of puffs during the fourth week of treatment